Literature DB >> 1693163

Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria.

B E Clarke1, A L Brown, K G Grace, G Z Hastings, F Brown, D J Rowlands, M J Francis.   

Abstract

We recently reported the enhanced immunogenicity of a peptide epitope when it was presented as a fusion protein with hepatitis B core antigen. In those experiments the fusion protein was expressed in vaccinia virus. We have now refined the system so that large amounts of highly immunogenic particles can be produced using a simple bacterial expression system. We describe the expression of three different viral epitopes as chimeric particles that induce good antibody responses to each epitope after one dose of low amounts of antigen. Finally we demonstrate that the immunogenicity is a reflection of both T helper cell sites within the core protein and also the particulate nature of the immunogens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693163     DOI: 10.1099/0022-1317-71-5-1109

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier.

Authors:  Jia-Yu Chen; Fan Li
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

2.  A protease-sensitive hinge linking the two domains of the hepatitis B virus core protein is exposed on the viral capsid surface.

Authors:  M Seifer; D N Standring
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

3.  Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer.

Authors:  Fan-Ping Meng; Jie Ding; Zhao-Cai Yu; Quan-Li Han; Chang-Cun Guo; Na Liu; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

4.  Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions.

Authors:  M A Chambers; G Dougan; J Newman; F Brown; J Crowther; A P Mould; M J Humphries; M J Francis; B Clarke; A L Brown; D Rowlands
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

5.  Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen.

Authors:  R Ulrich; G P Borisova; E Gren; I Berzin; P Pumpen; R Eckert; V Ose; H Siakkou; E J Gren; R von Baehr
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

6.  Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus.

Authors:  M J Francis; G Z Hastings; F Brown; J McDermed; Y A Lu; J P Tam
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

Review 7.  Use of hepadnavirus core proteins as vaccine platforms.

Authors:  David C Whitacre; Byung O Lee; David R Milich
Journal:  Expert Rev Vaccines       Date:  2009-11       Impact factor: 5.217

8.  The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.

Authors:  F Schödel; A M Moriarty; D L Peterson; J A Zheng; J L Hughes; H Will; D J Leturcq; J S McGee; D R Milich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

9.  Cytotoxic T cell responses in patients with chronic hepatitis B virus infection undergoing HBe antigen/antibody seroconversion.

Authors:  J A Waters; S O'Rourke; H J Schlict; H C Thomas
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

10.  Parvovirus particles as platforms for protein presentation.

Authors:  K Miyamura; S Kajigaya; M Momoeda; S J Smith-Gill; N S Young
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.